STING signaling: a key to therapeutic tumor immunity.
作者信息
Foote Jeremy B, Emens Leisha A
机构信息
Department of Microbiology, University of Alabama at Birmingham, School of Medicine, Birmingham AL, 35294, USA.
Department of Oncology, Bloomberg-Kimmel Institute at Johns Hopkins, Baltimore, MD 21287, USA.
出版信息
Immunotherapy. 2018 Jul;10(9):729-731. doi: 10.2217/imt-2018-0064.
PMID:30008260
Abstract
摘要
相似文献
1
STING signaling: a key to therapeutic tumor immunity.干扰素基因刺激蛋白信号传导：肿瘤免疫治疗的关键
Immunotherapy. 2018 Jul;10(9):729-731. doi: 10.2217/imt-2018-0064.
2
Introduction: Cancer Immunology Special Issue-Immunotherapy.引言：癌症免疫学特刊——免疫疗法。
Int Immunol. 2016 Jul;28(7):317. doi: 10.1093/intimm/dxw028. Epub 2016 Jun 15.
3
Coinhibitory Pathways in Immunotherapy for Cancer.癌症免疫治疗中的共抑制途径。
Annu Rev Immunol. 2016 May 20;34:539-73. doi: 10.1146/annurev-immunol-032414-112049. Epub 2016 Feb 25.
4
Part I: Checkpoint inhibitors in cancer therapy.第一部分：癌症治疗中的检查点抑制剂。
Immunotherapy. 2016 Jun;8(6):675-6. doi: 10.2217/imt-2016-0051.
5
PD-1/PD-L1 in disease.疾病中的程序性死亡受体1/程序性死亡配体1
Immunotherapy. 2018 Feb;10(2):149-160. doi: 10.2217/imt-2017-0120.
6
Neoantigen heterogeneity: a key driver of immune response and sensitivity to immune checkpoint blockade?新抗原异质性：免疫反应及对免疫检查点阻断敏感性的关键驱动因素？
Immunotherapy. 2016 Jun;8(7):763-6. doi: 10.2217/imt-2016-0064.
7
The present status and future prospects of peptide-based cancer vaccines.基于肽的癌症疫苗的现状与未来前景。
Int Immunol. 2016 Jul;28(7):319-28. doi: 10.1093/intimm/dxw027. Epub 2016 May 28.
8
Immunotherapy: a 10-year anniversary issue.免疫疗法：十周年特刊。
Immunotherapy. 2019 Feb;11(2):61-62. doi: 10.2217/imt-2018-0189.
9
PD-1 and PD-L1 in cancer immunotherapy: clinical implications and future considerations.PD-1 和 PD-L1 在癌症免疫治疗中的作用：临床意义和未来思考。
Hum Vaccin Immunother. 2019;15(5):1111-1122. doi: 10.1080/21645515.2019.1571892. Epub 2019 Mar 19.
10
Inflammation in the Tumor Microenvironment.肿瘤微环境中的炎症
J Immunol Res. 2018 Jun 24;2018:1965847. doi: 10.1155/2018/1965847. eCollection 2018.
Zotero 插件